Simon P. Heaton
Esperion Therapeutics (United States)(US)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Cancer Mechanisms and Therapy, Enzyme function and inhibition, Biochemical and Molecular Research, Microtubule and mitosis dynamics
Most-Cited Works
- → First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors(2011)541 cited
- → AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis(2007)356 cited
- → Discovery, Synthesis, and in Vivo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase(2007)273 cited
- → The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models(2012)111 cited
- → Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors(2006)92 cited
- → AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity(2012)91 cited
- → Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930(2010)86 cited
- → Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers(2014)79 cited
- → Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity(2008)64 cited
- → Fair Trade marketing: an exploration through qualitative research(2006)63 cited